The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) took a tepid step toward keeping and/or possibly discarding procedural volume requirements for new and continuing ...

This paper summarizes the implications of recent TAVR program expansion, supports the 2019 multisociety expert consensus recommendation of Level 1 and Level 2 valve centers, and defines the important ...

For 14 years, patient access to TAVR has been restricted for Medicare beneficiaries under a Coverage with Evidence Development requirement. This could change by June 15.

Four cardiology societies issued a joint statement for requirements for centers with existing or new transcatheter aortic valve replacement (TAVR) programs, which updates a 2012 statement. The new ...

Boston Scientific is discontinuing sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement systems. The Marlborough, MA-based company added that it would not pursue ...

Add Yahoo as a preferred source to see more of our stories on Google. Mar. 13—Union Health on Wednesday announced it has performed its 500th successful TAVR procedure, or transcatheter aortic valve ...

Each February during American Heart Month, there’s an increased focus on heart disease – the leading cause of death in the U.S. But the focus is often limited to the most common form, coronary heart ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Real-world mortality complicates reassurances in trial results ...

RANCHO MIRAGE, Calif., Jan. 4, 2024 /PRNewswire/ -- Eisenhower Health is the first hospital in the United States to become an Edwards Benchmark program Case Observation Site for the treatment of ...

Shasta Regional Medical Center staff are marking a significant milestone with a minimally invasive heart procedure. It’s called transcatheter aortic valve replacement (TAVR). They completed their ...

Boston Scientific’s decision to recall its Lotus Edge transcatheter aortic valve replacement product and end the program took us by surprise, and we’re moderately lowering our fair value estimate by ...